Docetaxel for Pembrolizumab-Refractory Recurrent Basal Cell Carcinoma. Sakai Y, Ogata D, Kurisaki M, Kase M, et al. J Dermatol 2026 Mar 27. doi: 10.1111/1346-8138.70244.

Read + Share

Amedeo Smart

Independent Medical Education

Sakai Y, Ogata D, Kurisaki M, Kase M, et al. Docetaxel for Pembrolizumab-Refractory Recurrent Basal Cell Carcinoma. J Dermatol 2026 Mar 27. doi: 10.1111/1346-8138.70244.
PMID: 41891435